Press Coverage

All press coverage

LTS expands into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business

Andernach, Germany – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Micro Array Patches (“MAP”) announces the signing of the acquisition of the Sorrel wearable injection device business (“Sorrel”) with headquarters in Netanya, Israel, a part of the Eitan Medical Ltd (“Eitan Medical”). The acquisition is a crucial step in LTS’ strategy to broaden its portfolio of drug delivery platforms. Sorrel’s large volume wearable injector technologies will enable LTS to go beyond its current passive technology offerings. It opens new opportunities for LTS to support pharma partners in the field of large molecules and biologics. 


This text is a press release from LTS LOHMANN Therapy Systems AG. The full text version of the article can be found here.

We are very delighted that we played a major role in this successful acquisition, which has enabled us to support LTS in making an important contribution to the further development of drug delivery options in the future.